Dataset Information

Ignition and flame stabilization of a strut-jet RBCC combustor with small rocket exhaust.

ABSTRACT: A Rocket Based Combined Cycle combustor model is tested at a ground direct connected rig to investigate the flame holding characteristics with a small rocket exhaust using liquid kerosene. The total temperature and the Mach number of the vitiated air flow, at exit of the nozzle are 1505 K and 2.6, respectively. The rocket base is embedded in a fuel injecting strut and mounted in the center of the combustor. The wall of the combustor is flush, without any reward step or cavity, so the strut-jet is used to make sure of the flame stabilization of the second combustion. Mass flow rate of the kerosene and oxygen injected into the rocket is set to be a small value, below 10% of the total fuel when the equivalence ratio of the second combustion is 1. The experiment has generated two different kinds of rocket exhaust: fuel rich and pure oxygen. Experiment result has shown that, with a relative small total mass flow rate of the rocket, the fuel rich rocket plume is not suitable for ignition and flame stabilization, while an oxygen plume condition is suitable. Then the paper conducts a series of experiments to investigate the combustion characteristics under this oxygen pilot method and found that the flame stabilization characteristics are different at different combustion modes.

SUBMITTER: Hu J

PROVIDER: S-EPMC3918380 | biostudies-other | 2014

REPOSITORIES: biostudies-other

ACCESS DATA

Similar Datasets

Project description:Importance:Stenting small-vessel lesions has an increased adverse cardiovascular event risk. Very thin-strut or ultrathin-strut drug-eluting stents might reduce this risk, but data are scarce. Objective:To assess the outcome of all-comer patients with small coronary vessel lesions treated with 3 dissimilar types of drug-eluting stents. Design:This is a prespecified substudy of the Comparison of Biodegradable Polymer and Durable Polymer Drug-eluting Stents in an All Comers Population (BIO-RESORT) trial, an investigator-initiated, randomized, patient-blinded comparative clinical drug-eluting stent trial. Patients treated with ultrathin-strut sirolimus-eluting stents, very thin-strut everolimus-eluting stents, or previous-generation thin-strut zotarolimus-eluting stents were enrolled from December 2012 to August 2015. This multicenter trial was conducted in 4 Dutch centers for cardiac intervention. Of all 3514 all-comer BIO-RESORT participants, 1506 patients with treatment in at least 1 small-vessel lesion (reference vessel <2.5 mm) were included. Data were analyzed between September 2018 and February 2019. Main Outcomes and Measures:Target lesion failure at 3-year follow-up, a composite of cardiac death, target vessel-related myocardial infarction, or target lesion revascularization, analyzed by Kaplan-Meier methods. Results:In 1452 of 1506 participants (96.4%) (1057 men [70.2%]; 449 women [29.8%]; mean [SD] age, 64.3 [10.4] years), follow-up was available. Target lesion failure occurred in 36 of 525 patients (7.0%) treated with sirolimus-eluting stents, 46 of 496 (9.5%) with everolimus-eluting stents, and 48 of 485 (10.0%) with zotarolimus-eluting stents (sirolimus-eluting vs zotarolimus-eluting hazard ratio [HR], 0.68; 95% CI, 0.44-1.05; P = .08; everolimus-eluting vs zotarolimus-eluting HR, 0.93; 95% CI, 0.62-1.39; P = .72). There was a difference in target lesion revascularizations between sirolimus-eluting and zotarolimus-eluting stents (2.1% vs 5.3%; HR, 0.40; 95% CI, 0.20-0.81; P = .009) that emerged after the first year of follow-up (1.0% vs 3.7%; P = .006); multivariate analysis showed that sirolimus-eluting stent implantation was independently associated with a lower target lesion revascularization rate at 3-year follow-up (adjusted HR, 0.42; 95% CI, 0.20-0.85; P = .02). In the everolimus-eluting stents, the revascularization rate was 4.0% (vs zotarolimus-eluting, HR, 0.74; 95% CI, 0.41-1.34; P = .31). There was no significant between-stent difference in cardiac death, target vessel myocardial infarction, or stent thrombosis. Conclusions and Relevance:Patients stented in small coronary vessels experienced fewer repeated revascularizations if treated with ultrathin-strut sirolimus-eluting stents vs previous generation thin strut zotarolimus-eluting stents. Further research is required to evaluate the potential effect of particularly thin stent struts. Trial Registration:ClinicalTrials.gov identifier: NCT01674803.

Dataset Information

Ignition and flame stabilization of a strut-jet RBCC combustor with small rocket exhaust.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets